Over 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL cholesterol (LDL-C) goal and remain at increased risk of ca…
The Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identifies and embraces technology that aims to improve mobility and daily life for people living with MSApplications are open worldwide to the tech community, innovators, design…
Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated reduced risk in total heart failure hospitalizations and car…
Sickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.63 vs 2.98) and the annual rate of days hospitalized (4 vs…
If approved, Mayzent® (siponimod) will be the first and only oral treatment specifically indicated for patients with active secondary progressive multiple sclerosis (SPMS) in Europe[1]) CHMP opinion is based on the Phase III EXPAND trial, the largest r…
The strategy is aligned with the Novartis Access Principles, which aim to systematically integrate access strategies in how the company researches, develops and delivers medicines globally A newly formed sub-Saharan Africa unit will deploy innovative a…
Interim results from COMPACT, a multi-country, real-world study of Erelzi for approved rheumatic diseases presented at 2019 ACR/ARP Annual Meeting US analysis of long-term financial impact when switching to biosimilar etanercept also presented, modelin…
42.2% of patients with non-radiographic axial spondyloarthritis (nr-axSpA) treated with Cosentyx had improved ASAS40 scores through Week 16; improvements continued through Week 52[1] PREVENT is the largest ever study of a biologic in patients with nr-a…